New Trial to Study Asthma Drug Responses, Genetic Factors in African-Americans | GenomeWeb

NEW YORK (GenomeWeb News) — The National Heart, Lung, and Blood Institute has launched a multi-site clinical trial to assess how African-Americans with asthma respond to different therapies, and to examine the genetics at play in those responses, NHLBI said today.

The Best African American Response to Asthma Drugs (BARD) study will enroll roughly 500 children and adults at 30 sites in 14 states to research their responses to varying combinations of medications and dosages and how genes may affect those responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.